Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice.
Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, Gabetti L, Mengozzi G, Williams TA, Rabbia F, Veglio F, Mulatero P.
J Am Coll Cardiol. 2017 Apr 11;69(14):1811-1820. PMID:28385310
Silvia Monticone (Italy)
1) Summarize your work in one sentence.
In the PATO study we evaluated the prevalence and the clinical phenotype of primary aldosteronism and its main subtypes (aldosterone producing adenoma and bilateral adrenal hyperplasia) in a large cohort of unselected hypertensive patients from primary care in Torino, Italy.
1) Summarize your findings in one sentence.
Around 6% of the general hypertensive population suffers from primary aldosteronism; affected patients are exposed to an increased risk of target organ damage and cardiovascular events compared with patients with essential hypertension and similar risk profile.
1) Which were the more important methods you used in this work?
If it is not a traditional method you can briefly explain the concept of that methodology.
All patients 18 to 60 years of age affected by arterial hypertension (newly diagnosed or previously diagnosed) consecutively presenting to the GP’s ofﬁce were invited to participate. The overall response rate was 51% and 1,672 patients were included in the study and evaluated for primary aldosteronism.
1) What did you learn from this paper, what was your take-home message?
Most hypertensive patients should be screened for primary aldosteronism, since it is a frequent cause of secondary hypertension, even in the general hypertensive population. Early diagnosis and specific treatment are fundamental to prevent the development of target organ damage and the development of cardiovascular events.